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Structured Abstract 19	  
Purpose: The aim of this paper is to present a simple and quantitative data analysis method 20	  
with a new potential in the application of liver SPECT imaging. We have established 21	  
quantitative SPECT/CT in vivo imaging protocols for determination of liver tumor burden 22	  
based on the known role of Kupffer cells in cancer of the liver. 23	  
Procedures: As it is also known that functional Kupffer cells accumulate particulate material 24	  
contained in the hepatic arterial blood supply, we used radiolabeled macro-aggregated 25	  
albumin particles ([99mTc]-MAA) injected intravenously to image liver disease. Quantification 26	  
of cold spot liver lesion imaging was also a general objective. Methods: We examined a 27	  
healthy control group (BALB/C mice, n=6) and group of induced hepatocellular carcinoma 28	  
(HCC, matrilin-2 transgenic KO mice, n=9), where hepatocellular carcinoma was induced by 29	  
diethylnitrosamine. As radiopharmaceutical we used [99mTc]-MAA for liver SPECT imaging 30	  
in a small animal SPECT/CT system. A liver radioactivity overview map was generated. 31	  
Segmentation of the liver was calculated by Otsu thresholding method. Based on the 32	  
segmentation the radioactivity volume and the summarized liver activity were determined.  33	  
Results: Liver tumour burden was quantitatively determined by creating parametric data from 34	  
the resulting volumetric maps. Ex vivo liver mass data were applied for the validation of in 35	  
vivo measurements. An uptake with cold spots as tumors was observed in all diseased animals 36	  
in SPECT/CT scans. Isotope labeled particle uptake (standardized uptake concentration – 37	  
SUC) of control (median 0.33) and HCC (median 0.18) groups was significantly different (p = 38	  
0.0015, Mann-Whitney U test). 39	  
Conclusion: A new potential application of [99mTc]-MAA was developed and presents a 40	  
simple and very effective means to quantitatively characterize liver cold spot lesions resulting 41	  
from Kupffer cell dysfunctions as a consequence of tumor burden.	  42	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Introduction 47	  
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality 48	  
worldwide and it is the most common primary cancer of the liver [1]. Furthermore liver 49	  
imaging is commonly undertaken in patients with tumorous anamnesis because the liver is 50	  
one of the most frequently involved organs by metastatic disease either as source or target [2]. 51	  
Several imaging modalities are now available for detection and characterization of tumorous 52	  
lesions in the liver: ultrasonography (US), computed tomography (CT), magnetic resonance 53	  
imaging (MRI), positron emission tomography (PET) and single photon emission computed 54	  
tomography (SPECT). The availability of combined functional/anatomical imaging modalities 55	  
that integrate the benefits of visualizing tumor biology with those of high-resolution structural 56	  
imaging revolutionized both clinical and pre-clinical imaging. The latter can be very 57	  
important to translate new, more specific and sensitive methods of liver cancer diagnostics as 58	  
well as therapeutic potential to the clinic. 59	  
In clinical practice the most commonly used liver tumor detection methods are based 60	  
on anatomical imaging techniques such as X-ray CT methods and different MRI-based 61	  
solutions – diffusion weighted imaging (DWI) and contrast enhanced T1-weighted imaging 62	  
and small paramagnetic iron oxide particle (SPIO) imaging. DWI tumor detection is based on 63	  
the phenomenon of decreased water molecule diffusion coefficients due to increased 64	  
cellularity levels in the lesion [3]. Contrast enhanced CT which is widely available and 65	  
familiar with the general radiologist is the mainstay of hepatic imaging [4]. The accuracy of 66	  
CT is poor at a smaller (<2 mm) tumor size therefore an MRI should be performed to fully 67	  
evaluate the liver however in these cases the false positive rate increases [5]. 68	  
Imaging radiolabeled compounds with SPECT and PET is often carried out to provide 69	  
insight into a tumor's biological functions. Despite their high sensitivity and specificity 70	  
	  	  
tomographic SPECT and PET are substantially limited by low spatial resolution and inability 71	  
to provide anatomical detail [6]. Some HCC specific radiopharmaceuticals as [11C]-acetate, 72	  
[11C]-choline and FDG are used in PET imaging [7-9]. Quantification of the metabolic rate of 73	  
tumor cells and its visualization in parametric images can provide an enhanced sensitivity of 74	  
diagnosis in dubious cases [10, 11]. More advantageous are those SPECT and PET imaging 75	  
methods that provide hot-spot imaging where radiopharmaceuticals or radiopeptides are 76	  
uptaken by tumours in a larger extent than healthy liver tissue. On the other hand, a widely 77	  
available radiotracer for uniformly positive HCC cell uptake in all or even the majority of 78	  
patients still can be considered missing, as [11C]-labeled compounds require special 79	  
radiochemistry and a nearby cyclotron, whereas [18F]-choline is not showing positive contrast 80	  
in tumors of all patients [12]. 81	  
In the past and in current clinical practice liver radio-scintigraphy and SPECT imaging 82	  
with macro-aggregated albumin ([99mTc]-MAA) or galactosyl human serum albumin ([99mTc]-83	  
GSA) [13, 14] are used to show the hepatic circulation. On the other hand these techniques 84	  
have rarely been reported being used to directly detect tumorous lesions. 85	  
In hepatocellular carcinoma the number of Kupffer cells is decreased or absent in the 86	  
tumor tissue [15, 16]. Previous papers have clearly demonstrated that [99mTc]-labeled 87	  
nanoparticles as sulfur colloids or MAA are taken up by Kupffer cells [17]. The method of 88	  
SPIO MR imaging is also based on Kupffer cell particle uptake and it shows the same 89	  
diagnostic sensitivity as other MRI techniques [18]. 90	  
We experimented with different clinically available radiotracers in our tumour model 91	  
to show selective and positive contrast imaging of liver HCC foci in mice. Although our effort 92	  
to obtain positive focal tumour contrast with several radiotracers for SPECT have not 93	  
provided satisfactory results, these experiments are also briefly referred in the Methods and 94	  
	  	  
Results section with the aim to provide the reader a more complete background on liver focus 95	  
imaging in this model. Based on previous literature data and our experience we supposed that 96	  
cold-spot imaging would have an important role in liver focus detection and follow-up. We 97	  
also hypothesized that the screening of Kupffer cells using MAA in SPECT imaging would be 98	  
a translatable and valid means to sensitively detect tumorous lesions in the liver as cold-spots. 99	  
According to previously published in vitro and clinical studies based on the correlation 100	  
between HCC and mean number of liver Kupffer cells, quantitative SPECT/CT in vivo 101	  
imaging methods and image analysis could estimate tumour grade and stage of liver lesions 102	  
too [16]. The aim of this article is to present a preclinical study and a simple data analysis 103	  
method that could show a new potential application of MAA for clinical practice too. 104	  
Therefore the often difficult interpretation of cold-spot images is made easier using the 105	  
analysis described herein. Our intention was to find an appropriate, simple, and 106	  
straightforward in vivo surrogate of tumor burden determination. It has paramount importance 107	  
that this method could be easily executed on in vivo in situ liver data. 108	  
 109	  
Material and methods 110	  
We examined a healthy control group (BALB/c, C3H, C57BL/6 mice, n=2-2-2, 111	  
m=34.2 +/- 11 g) and a HCC group (cancer-prone matrilin-2 transgenic KO mice (MATN2) 112	  
with chemically induced hepatocellular carcinoma, n=9, m=38.5 +/- 2 g). Hepatocellular 113	  
carcinoma was induced by diethylnitrosamine on 15 days old male mice via intraperitoneal  114	  
injection. The imaging was performed 4 months after induction. The presence of tumorous 115	  
lesions was proved by histology in Haematoxylin-Eosin stained 10 µm thin sections 116	  
(Supplementary Figure 1). All our experiments were conducted according to applicable 117	  
national and European Union legislation and previously obtained the ethical approval of the 118	  
	  	  
Municipal and the Local Animal Care and Use Committee. (Permission Nr. XIV-I-001/29-119	  
7/2012). 120	  
In preparation, our group has experimented with different other radiotracers to enable 121	  
selective and positive contrast imaging of HCC models in mice. In previous proof-of-concept 122	  
experiments in groups of n=4 mice of the same HCC-induced model we applied [99mTc]-123	  
methoxy-isobutyl-isonitrile (MIBI) – Medi-MIBI®, Medi-radiopharma Ltd, Budapest, 124	  
Hungary (cca. 60 MBq iv per animal, imaging 20 minutes post injection), [99mTc]-125	  
dimercaptosuccinate (DMSA(V), cca. 80 MBq per animal, imaging 3 hours post injection – 126	  
Penta-DMSA®, Medi-Radiopharma Ltd., Budapest, Hungary) and [201Tl]-thallous chloride 127	  
(cca. 24 MBq per animal, 4 and 24 hours post injection, IBV, Petten). 128	  
For [99mTc]-Technetium labeling, a commercially available [99mTc]-generator was used 129	  
(Sorin-Drygen, Izotop, Budapest, Hungary). 130	  
Animals were anesthetized by the injection of 800 mg/kg body weight dose of 10% 131	  
solution ofurethane injection intraperitoneally (ip.). We used [99mTc]-MAA (Nano-Albumon, 132	  
Medi-radiopharma Ltd, Budapest, Hungary, mean diameter 200 nm, with 2-5 GBq/mg 133	  
specific activity), as radiopharmaceutical for Kupffer-cell imaging (0.1-0.22 ml, 90 134	  
MBq/animal (Atotal) iv, 2 hours post injection) for helical liver SPECT imaging (17-18 min 135	  
scan time) with a voxel size of 200 um, and eXIA160 (Binitio Biomedical, Inc., Ottawa, CA) 136	  
small animal contrast material (0.1 ml / 20 g iv, 2 hours post injection imaging) for liver CT 137	  
imaging to enhance liver contrast (9 min scan time) with voxel size of 36 um 138	  
(NanoSPECT/CT Plus Silver Upgrade, Mediso Ltd., Hungary). The segmentation of the liver 139	  
images were processed first by visually delineating a Volume of Interest containing only the 140	  
liver and the body as background (this process was assisted by the CT image). Thereafter 141	  
Otsu thresholding method was run on this segmented SPECT image volume in VivoQuant 142	  
	  	  
(inviCRO, Boston, USA) image analysis software to obtain a reliable and automatic 143	  
delineation of liver versus non-liver volumes [19]. Based on the segmentation the 144	  
radioactivity volume (Vliver) and the summarized liver activity (Aliver) were determined. 145	  
Several semi quantitative techniques may be used to express the accumulation of radiotracers 146	  
in tumours and normal tissues, including SUV (standardized uptake value). This has been 147	  
described as a method of expressing biologic tissue distribution or relative concentration of 148	  
radiotracers following iv administration in a variety of species [20, 21]. 149	  
In our process a measurand called Standardized Uptake Concentration (SUC, Eq1.) 150	  
per animal were obtained from quantified SPECT data [22]. 151	  
Eq1.  
SUC=
Aliver
AtotalV liver  152	  
After the last imaging session the animals were culled by ip. injection of 0.5 mL of 153	  
euthanasia agent (T61®, Bayer, Germany) and an autopsy was performed. The livers were 154	  
carefully removed by hand, placed in a filter paper sheet and then mass of each animal’s liver 155	  
was measured using an ABJ220-4M Precision Balance (Kern & Sohn GmbH, Balingen, 156	  
Germany) with 0.1 g precision. Ex vivo liver tumor mass was used as objective parameter and 157	  
was applied for the validation of in vivo measurements to correlate tumor burden measured by 158	  
SPECT and in vivo really present tumor mass in the liver. 159	  
 160	  
Statistical calculations 161	  
To compare control and HCC groups, Mann-Whitney U-test was applied. To check the 162	  
relationship between ex vivo liver mass and segmented liver volume (ie. to account for 163	  
validity of SPECT measurement segmentation), Spearman’s correlation test was used. 164	  
 165	  
	  	  
Results 166	  
Positive tumour focus contrast SPECT imaging was not achievable in our experience 167	  
by the applied radiotracers [99mTc]-MIBI, [99mTc]-DMSA(V) or [201Tl]-chloride.  168	  
In Figure 1. images show the CT reconstruction of the whole body with a window to 169	  
present the skeleton (left), the 99mTc isotope labeled MAA uptake in liver segmented by Otsu 170	  
method 2 hours after the injection (center) and the 3D VOI created on the basis of the SPECT 171	  
images. Based on this process the livers of all the animals were segmented. 172	  
In our experiment [99mTc]-MAA was detectable mainly in the liver and the bladder 173	  
after two hours. The mean ratio of liver and whole body activity was 42% (SD: 6% ) and 51% 174	  
(SD: 5%) in the HCC and control group respectively. Figure 2. presents slices of SPECT and 175	  
CT reconstructed liver images. Fig. 2A shows CT image of a healthy control without contrast 176	  
material and Fig. 2B shows CT image of a HCC mouse with contrast material. SPECT image 177	  
of a healthy control (Fig. 2C) shows homogenous uptake. On the other hand HCC (Fig. 2D) 178	  
was acquired and the tumorous regions as several cold spots – largest on the left lobe - could 179	  
be detected. (Other SPECT images of different animals are available as supplementary 180	  
materials.) For quantification purposes the SUC (Eq. 1.) was defined being similar to the SUV 181	  
parameter in PET experiment. We based our SUC measurements on a quantitative, previously 182	  
calibrated SPECT system. This quantitative parameter helps to estimate the presence of the 183	  
lesion/cancer, the volume of the lesion and the severity of the cancer. 184	  
Based on literature data we suppose relationship of in vivo defect volumes and tumor 185	  
volumes [23]. The validation of liver segmentation was examined by establishing the 186	  
correlation between volume via in vivo segmentation and ex vivo liver mass of HCC group. 187	  
(Spearman correlation r=0.93, p < 0.001). Liver volume was plotted against liver mass as 188	  
presented in Fig. 3. 189	  
	  	  
In Figure 4. the box plot shows the SUC of control (median 0.33) and HCC (median 190	  
0.18) groups. The difference is statistically significant (p = 0.0015, Mann-Whitney U test). 191	  
 192	  
Discussion and Conclusions 193	  
 Based on the results of the SPECT imaging 2 hours after the radiopharmaceutical 194	  
injection we can conclude that the [99mTc]-MAA is accumulated in the liver. In this time 195	  
frame the MAA was not detectable in the heart and in the blood vessels. Based on literature 196	  
data we suppose that [99mTc]-MAA was taken up by Kupffer cells which are the specialized 197	  
resident macrophage cells of the liver [17]. The intravenously injected large sized and long 198	  
circulating nanoparticles are recognized by Kupffer cells via a multitude of specialized 199	  
plasma membrane receptors [24]. The mechanisms of uptake are phagocytosis and 200	  
macropinocytosis mediated by complement receptors after relatively nonspecific opsonization 201	  
with complement and by Fc receptors after specific opsonization with antibodies [25]. 202	  
 We could observe the uptake absence - cold spots - as tumorous lesions in SPECT 203	  
images in all cases of diseased animals. The CT imaging has disadvantages such as longer 204	  
segmentation and image processing time. Furthermore the SPECT radiopharmaceutical 205	  
[99mTc]-MAA is much more economical than the available small animal CT contrast agents. 206	  
Because of the functional nature of [99mTc]-MAA SPECT we have information on 207	  
cellular and even metabolic level uptake of macro-aggregates that is an indirect marker of the 208	  
intact functioning of the Monocyte-Macrophage System (MMS) in the liver. Thus, the 209	  
information content of these functional images is much more than identifying visible focal 210	  
lesions – but that information is hidden in the data acquired. The quantitative SUC parameter 211	  
could present one facet of this additional information. We hereby show the applicability of the 212	  
SUV concept in quantitative SPECT studies. We found that the distribution of SUC values is 213	  
	  	  
significantly different in the tumorous and control group. Therefore, the SUC value could be a 214	  
useful tool to differentiate between healthy and tumorous sub-volumes of the liver SPECTs. 215	  
This study suggests that SPECT with [99mTc]-MAA can estimate both the presence 216	  
and the size of tumorous lesions in the liver using a specific data analysis method. The results 217	  
are promising for later preclinical and clinical practice. Nevertheless, due to the specific 218	  
model of chemically induced HCC in contrast to the mostly viral origin human HCC 219	  
morbidities, and in principle the sample sizes applied in our study would also warrant for 220	  
thorough examination before the clinical translation. 221	  
On the other hand, our method proposed hereby is straightforward and can be applied 222	  
with minimal changes of the imaging device, the patient protocol and needs only a small data 223	  
analysis experience. For pre-clinical use the method would become a very powerful tool of 224	  
high-content in-vivo hepatotoxicity testing after repeated or even single exposition of new 225	  
chemical entities. 226	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Figures 239	  
 240	  
Fig 1. NanoSPECT/CT study in healthy control and HCC mouse model with [99mTc]-MAA. 241	  
The images show the CT reconstruction and the isotope labeled nanoparticle uptake in liver 2 242	  
hours after MAA injection segmented by Otsu method and the delineation of the VOI. 243	  
 244	  
Fig 2. NanoSPECT/CT study in healthy control and HCC mouse model with [99mTc]-MAA. 245	  
a) CT image of healthy control without contrast material b) CT image of HCC with contrast 246	  
material (eXIA160) c) SPECT image of healthy control d) SPECT image of HCC. 247	  
 248	  
Fig 3. The validation of segmentation is proven by correlation between volume via in vivo 249	  
segmentation and ex vivo liver mass of HCC group (Spearman, r=0.93 p < 0.01%). 250	  
 251	  
Fig 4. The box plot shows the SPECT-based quasi Standardized Uptake Value (SUC) of 252	  
[99mTc]-MAA of control (median 0.33) and HCC (median 0.18) groups. The difference is 253	  
statistically significant (p < 0.0015, Mann-Whitney U test). 254	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